UroGen Pharma URGN Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's accounts payable and other current liabilities (note 11)?
- UroGen Pharma (URGN) reported accounts payable and other current liabilities (note 11) of $35.35M in Q1 2026.
- How has UroGen Pharma's accounts payable and other current liabilities (note 11) changed year-over-year?
- UroGen Pharma's accounts payable and other current liabilities (note 11) increased by 16.6% year-over-year, from $30.32M to $35.35M.
- What is the long-term trend for UroGen Pharma's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), UroGen Pharma's accounts payable and other current liabilities (note 11) has grown at a 22.6% compound annual growth rate (CAGR), from $10.02M to $27.72M.